In trials, Cagrilintide and semaglutide combination showed nearly double the weight loss compared to semaglutide alone
Both medications are trusted and effective, but they arent identical
A population-based study of 467 matched pairs of GLP-1 users and non-users with type 2 diabetes and liver cirrhosis found GLP-1 use associated with lower risks of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure
The combination group experienced faster and greater repigmentation overall, with stronger differences reported on the face and upper extremities
The dosage comparison charts between the two medications help visualize the escalation differences
Why Tirzepatide Is Being Discussed in MS The discussion starts with metabolism, not with a proven neurologic benefit